These include determining the optimal timing of treatment with the WEE1 inhibitor and DNA-damaging components of chemotherapy, understanding the impact of WEE1 inhibition on the genomic integrity of normal cells and tissue, and whether WEE1 inhibition can sensitize CRC cells to DNA-damaging agents [529,547,548]. This evidence concerns the gene WEE1 and colorectal carcinoma.